Electromedical Products International, Inc.
7
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
28.6%
2 terminated/withdrawn out of 7 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
CES for the Treatment of GAD in Young Adults
Role: lead
Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders
Role: collaborator
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Depression
Role: lead
Neural Mechanisms With CES in Depression
Role: lead
Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder
Role: lead
Clinical and Cost Effectiveness of Alpha-Stim AID CES
Role: lead
Alpha-Stim AID and Major Depressive Disorder
Role: lead
All 7 trials loaded